{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:19Z","timestamp":1792461079618,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZY2017202"],"award-info":[{"award-number":["ZY2017202"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.biopha.2021.111373","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:41:47Z","timestamp":1614127307000},"page":"111373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Studies on the anti-psoriasis effects and its mechanism of a dual JAK2\/FLT3 inhibitor flonoltinib maleate"],"prefix":"10.1016","volume":"137","author":[{"given":"Jiali","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heying","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9583","key":"10.1016\/j.biopha.2021.111373_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005268","article-title":"Psoriasis clinical implications and treatment: a review","volume":"30","author":"Raut","year":"2013","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"issue":"7130","key":"10.1016\/j.biopha.2021.111373_bib3","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0001-7310(09)73372-1","article-title":"Progress in understanding the immunopathogenesis of psoriasis","volume":"100","author":"Mak","year":"2009","journal-title":"Actas Dermosifiliogr."},{"issue":"5","key":"10.1016\/j.biopha.2021.111373_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111373_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12016-007-0039-2","article-title":"Immunopathogenesis of psoriasis","volume":"33","author":"Nickoloff","year":"2007","journal-title":"Clinic. Rev. Allerg. Immunol."},{"issue":"18","key":"10.1016\/j.biopha.2021.111373_bib8","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/14656566.2017.1409205","article-title":"Advances in treating psoriasis in the elderly with small molecule inhibitors","volume":"18","author":"Cline","year":"2017","journal-title":"Expert. Opin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1523-1747.ep12612745","article-title":"Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate","volume":"104","author":"Jeffes","year":"1995","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.biopha.2021.111373_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.0906-6705.2004.00177.x","article-title":"Methotrexate markedly reduces the expression of vascular E\u2010selectin, cutaneous lymphocyte\u2010associated antigen and the numbers of mononuclear leucocytes in psoriatic skin","volume":"13","author":"Sigmundsdottir","year":"2004","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/eji.200324174","article-title":"Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses","volume":"34","author":"Litjens","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","article-title":"Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"17","key":"10.1016\/j.biopha.2021.111373_bib13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMc1300283","article-title":"Manufacturer\u2019s response to case reports of PML","volume":"368","author":"Sweetser","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111373_bib14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double\u2010blind placebo\u2010controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111373_bib15","first-page":"1093","article-title":"Anti-IL-23 Phase II data for psoriasis: a review","volume":"14","author":"Beroukhim","year":"2015","journal-title":"J. Drugs Dermatol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2310\/7750.2013.13125","article-title":"Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab","volume":"18","author":"Tausend","year":"2014","journal-title":"J. Cutan. Med. Surg."},{"issue":"9","key":"10.1016\/j.biopha.2021.111373_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"14","key":"10.1016\/j.biopha.2021.111373_bib18","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1242\/dev.02411","article-title":"JAK\/STAT signalling in drosophila: insights into conserved regulatory and cellular functions","volume":"133","author":"Arbouzova","year":"2006","journal-title":"Development"},{"issue":"2014","key":"10.1016\/j.biopha.2021.111373_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"3","author":"Hsu","year":"2014","journal-title":"J. Immunol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib20","doi-asserted-by":"crossref","first-page":"e12555","DOI":"10.1111\/dth.12555","article-title":"Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors","volume":"30","author":"Wcis\u0142o-Dziadecka","year":"2017","journal-title":"Dermatol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jdv.13808","article-title":"Effect of tofacitinib withdrawal and re\u2010treatment on patient\u2010reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Griffiths","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib22","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111373_bib23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.biopha.2021.111373_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.biopha.2021.111373_bib25","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2021.111373_bib26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/13543784.17.11.1685","article-title":"FLT3 inhibitors for the treatment of autoimmune disease","volume":"17","author":"Whartenby","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"Suppl 7","key":"10.1016\/j.biopha.2021.111373_bib27","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.4103\/0378-6323.115532","article-title":"Newer targeted therapies in psoriasis","volume":"79","author":"Khandpur","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.autrev.2013.09.010","article-title":"Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation","volume":"13","author":"Ramos","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.20030107","article-title":"The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3","volume":"198","author":"D\u2019Amico","year":"2003","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111373_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12026-014-8521-4","article-title":"Accumulation of FLT3+CD11c+ dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor","volume":"60","author":"Yan","year":"2014","journal-title":"Immunol. Res."},{"issue":"18","key":"10.1016\/j.biopha.2021.111373_bib32","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1021\/acs.jmedchem.6b00604","volume":"59","author":"Li","year":"2016","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4049\/jimmunol.172.3.1355","article-title":"Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2\/Stat4 signaling pathway","volume":"172","author":"Chiang","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib34","doi-asserted-by":"crossref","first-page":"e9593","DOI":"10.1371\/journal.pone.0009593","article-title":"Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock","volume":"5","author":"Zhong","year":"2010","journal-title":"Plos One"},{"issue":"22","key":"10.1016\/j.biopha.2021.111373_bib35","doi-asserted-by":"crossref","first-page":"10305","DOI":"10.1021\/acs.jmedchem.9b01348","article-title":"Discovery of potent and orally effective dual Janus kinase 2\/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1358\/dof.2013.38.6.1964716","article-title":"Pacritinib. Inhibitor of tyrosine-protein kinase JAK2, inhibitor of FLT-3, treatment of myelofibrosis","volume":"38","author":"Verstovsek","year":"2013","journal-title":"Drugs Fut."},{"issue":"11","key":"10.1016\/j.biopha.2021.111373_bib37","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1038\/bcj.2011.43","article-title":"Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia","volume":"1","author":"Hart","year":"2011","journal-title":"Blood Cancer J."},{"issue":"13","key":"10.1016\/j.biopha.2021.111373_bib38","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1021\/jm200326p","volume":"54","author":"William","year":"2011","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2021.111373_bib39","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1084\/jem.20100559","article-title":"Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation","volume":"207","author":"Huggenberger","year":"2010","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111373_bib40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/jid.2009.43","article-title":"Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis","volume":"129","author":"Wang","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111373_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1523-1747.1999.00538.x","article-title":"Animal models of psoriasis \u2013 what can we learn from them?","volume":"112","author":"Schon","year":"1999","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00109-015-1338-3","article-title":"Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-\u03baB and proinflammatory cytokines","volume":"94","author":"Wu","year":"2016","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111373_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2002-12-3793","article-title":"Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis","volume":"102","author":"Xia","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biopha.2021.111373_bib44","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.4049\/jimmunol.0902464","article-title":"Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1\u03b1, and TNF-\u03b1 recapitulates some features of psoriasis","volume":"184","author":"Guilloteau","year":"2010","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib45","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.4049\/jimmunol.175.6.3674","article-title":"Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity","volume":"175","author":"Tussiwand","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111373_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","article-title":"An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow","volume":"223","author":"Lutz","year":"1999","journal-title":"J. Immunol. Methods"},{"issue":"20","key":"10.1016\/j.biopha.2021.111373_bib47","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.biopha.2021.111373_bib48","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Fits","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2021.111373_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/ced.13148","article-title":"Systemic ALA\u2010PDT effectively blocks the development of psoriasis\u2010like lesions and alleviates leucocyte infiltration in the K14\u2013VEGF transgenic mouse","volume":"42","author":"Chen","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"issue":"7","key":"10.1016\/j.biopha.2021.111373_bib50","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.1992.tb07805.x","article-title":"Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?","volume":"126","author":"Baker","year":"1992","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib52","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.4049\/jimmunol.1600446","article-title":"IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1\/M2 macrophage ratio in psoriasis","volume":"197","author":"Zhang","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2021.111373_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lfs.2019.03.018","article-title":"DUSP1\/MKP-1 regulates proliferation and apoptosis in keratinocytes through the ERK\/Elk-1\/Egr-1 signaling pathway","volume":"223","author":"Yang","year":"2019","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.111373_bib54","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1111\/j.1365-4632.2012.05611.x","article-title":"Anthralin\/dithranol in dermatology","volume":"53","author":"Sehgal","year":"2014","journal-title":"Int. J. Dermatol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib55","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1021\/mp200327k","article-title":"Therapeutic and cytotoxic effects of the novel antipsoriasis codrug, naproxyl-dithranol, on HaCaT cells","volume":"8","author":"Lau","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2021.111373_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1290\/1543-706X(2003)039<0036:COAEOE>2.0.CO;2","article-title":"Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay","volume":"39","author":"Pol","year":"2003","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"issue":"4","key":"10.1016\/j.biopha.2021.111373_bib57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00011-020-01322-4","article-title":"Igalan from Inula helenium (L.) suppresses the atopic dermatitis-like response in stimulated HaCaT keratinocytes via JAK\/STAT3 signaling","volume":"69","author":"Dao","year":"2020","journal-title":"Inflamm. Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib59","first-page":"8385","article-title":"The therapeutic effect of artesunate on rosacea through the inhibition of the JAK\/STAT signaling pathway","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"45","key":"10.1016\/j.biopha.2021.111373_bib60","doi-asserted-by":"crossref","first-page":"19455","DOI":"10.1073\/pnas.1008271107","article-title":"Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling","volume":"107","author":"Rochman","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.biopha.2021.111373_bib61","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1136\/ard.2011.150102","article-title":"Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2021.111373_bib62","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib63","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a Phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111373_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213344","article-title":"Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8\/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8\/A9 protein levels in serum","volume":"14","author":"Duvetorp","year":"2019","journal-title":"Plos One"},{"issue":"17","key":"10.1016\/j.biopha.2021.111373_bib65","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1016\/j.bmc.2017.07.042","article-title":"9,19-Cycloartenol glycoside G3 from Cimicifuga simplex regulates immune responses by modulating Th17\/Treg ratio","volume":"25","author":"Su","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2021.111373_bib66","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111373_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1196\/annals.1392.015","article-title":"Flt3 in regulation of type I interferon-producing cell and dendritic cell development","volume":"1106","author":"Onai","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2021.111373_bib68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5306\/wjco.v9.i5.90","article-title":"Resistance to FLT3 inhibitors in acute myeloid leukemia: molecular mechanisms and resensitizing strategies","volume":"9","author":"Zhou","year":"2018","journal-title":"World J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111373_bib69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1101\/gad.14.2.232","article-title":"Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation","volume":"14","author":"Kieslinger","year":"2000","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.biopha.2021.111373_bib70","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1074-7613(03)00332-7","article-title":"STAT3 is required for Flt3L-dependent dendritic cell differentiation","volume":"19","author":"Laouar","year":"2003","journal-title":"Immunity"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222100158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:36:32Z","timestamp":1760099792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222100158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":70,"alternative-id":["S075333222100158X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111373","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Studies on the anti-psoriasis effects and its mechanism of a dual JAK2\/FLT3 inhibitor flonoltinib maleate","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111373"}}